Oral Biopharmaceutics and Absorption Modeling Community

 View Only

AAPSbutton2.png
If you're not a member of this community and would like to join it, click the orange Join button.

Leadership

Chair: Deanna Mudie | Vice Chair: TBD | Past Chair: Siddhi Hate | Secretary: Grazyna Fraczkiewicz | Learning Opportunities Managers: Suvarchala Avvari, Rodrigo Cristofoletti, Shriram Pathak, Siladitya Chaudhuri, Paul Seo, Bart Hens, Niloufar Salehi | Member Engagement Managers: Nikoletta Fotaki, Maria Vertzoni, David Turner, Yasuhiro Tsume, Maiara Camotti Montanha, Kevser Sevim, Ana Coutinho | Scientific Advisory Committee Regulatory Response Subcommittee Members: Maria Vertzoni

2025 Goals for the Oral Biopharmaceutics and Absorption Modeling Community (PDF)


Community email address: aaps-oralbiopharmaceuticsandabsorptionmodelingcommunityo@connectedcommunity.org

​​​​​​​​

Latest Discussion Posts

Please login to see all eligible discussion postings.

Reach out to [email protected] if you need assistance.

Announcements

  • OBAM Community Meeting at Pharmsci 360

    Please join us for our in person community meeting at Pharmsci 360. I hope to see you there!

    Time: Tuesday, October 22 at 4 pm Mountain Time.

    Location: Spotlight Stage C, Aisle 2800, Exhibit Hall
    Salt Palace Convention Center

    More
  • JUNE 12 - Cannabinoid-based Research and Development: How to Increase the Odds

    Cannabinoids, such as cannabidiol (CBD) hold great therapeutic promise as shown by both established (epilepsy, sclerosis) and emerging (psychosis, anxiety, mood, and sleep disorders, addiction, pain etc.) science. However, currently available delivery formats for cannabinoid medicine as well as ongoing R&D face challenges with regard to API absorption and patient compliance. Firstly, formulating with CBD can be challenging due to its variable oral bioavailability. Stability, solubility, and mode of administration all play a role in the rate of absorption of CBD. The oral bioavailability of CBD has been shown to be very low in humans (6%), as a result of incomplete absorption in the gut and significant pre-systemic elimination in the liver. It is estimated that up to 75% of orally absorbed CBD is removed by hepatic metabolism. Bioavailability of the active is directly linked to its therapeutic efficacy and the dose required to achieve a response. It is therefore important to identify solutions to enhance the bioavailability of CBD and other cannabinoids. The currently preferred option of medicine manufacturers to overcome this hurdle is delivering CBD in an oil vehicle because CBD absorption is increased in the presence of fatty foods. And it has been a smart choice with the technologies we have had at hand. But that comes with its own challenges regarding patient convenience, patient compliance, and a proven high variability between patients. Consuming large volumes of oil to reach the prescribed dose is not pleasant or easy. When it comes to children or people with a difficulty swallowing, it is almost impossible. Addressing this will make a difference for patient acceptance. In this session we would like to share the learnings from a two-year technology assessment process whereby our formulation and application scientists examined more than 200 prototypes and tested in vitro and in vivo several technologies for improving the bioavailability of CBD while enabling patient-friendly formats such as orodispersible tablets, chewables, capsules, and other oral delivery formats with high API loading.

    More

Latest Shared Files

Log in to see this information

Reach out to [email protected] if you need assistance.